Finance & Corporate

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

Tue, 01/19/2021 - 09:30

NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studie

Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

Thu, 05/07/2020 - 10:30

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

ElsaLys Biotech at BIO-Europe 2018

Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

ELSALYS BIOTECH announces the completion of the first instalment of a total fundraising amounting to € 5 million

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

Tue, 07/18/2017 - 17:00

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®, an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

Thu, 10/12/2017 - 17:00

In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Copyright 2021 ElsaLys Biotech SA